November 2007 Oncology News International

Article

Cover Story


DEPARTMENTS



Focus on Breast Cancer

News & Analysis

Focus on Hematology

Focus on Colon Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The safety profile of teclistamab-based therapy in the MajesTEC-5 trial was expected based on the known compounds employed in each combination.
It may be critical to sequence BCL-2 inhibitors with BTK inhibitors for patients with mantle cell lymphoma in the relapsed/refractory setting.
Related Content
ISB 2001 Yields Durable Responses, Manageable Safety in R/R Multiple Myeloma

ISB 2001 Yields Durable Responses, Manageable Safety in R/R Multiple Myeloma

Ashling Wahner
September 18th 2025
Article
Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.

Gathering the Latest Multidisciplinary Care Insights Across World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mehmet Asim Bilen, MD;Sid Sadler;Kerry R. Schaffer, MD;Mark T. Fleming, MD;Jeff Yorio, MD;Mike Lattanzi, MD;Elizabeth Kessler, MD;Benjamin L. Maughan, MD, PharmD;Alan Tan, MD
September 18th 2025
Podcast
An independent data monitoring committee recommended the continuation of the phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in PDAC in August 2025.

ELI-002 7P Elicits T Cell Responses in Mutant KRAS-Driven Tumors

Roman Fabbricatore
September 18th 2025
Article
Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 18th 2025
Podcast
Additional time is necessary to confirm the depth and durability of responses observed in the phase 1 CAMMA 1 study.

Cevostamab Combo Shows Enduring Responses in R/R Multiple Myeloma

Ashling Wahner
September 18th 2025
Article
Improving Leukoplakia Follow-Up: Information Leaflets, Habit Cessation Counseling

Improving Leukoplakia Follow-Up: Information Leaflets, Habit Cessation Counseling

Shaila Mulki, PhD, MDS;Seema Mavinapalla, MDS;Supriya Hulimane, MDS;Elizabeth Sojan, MDS;Deviprasad Nooji, MDS;Vidya Gowdappa Doddawad, MDS
September 18th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.